Strategic Psychopharmacology in the Treatment of Schizophrenia and Other Psychiatric Conditions

All Sessions Will Be Held in Pacific Time (PT)

Historically, or available treatments for serious mental health conditions (such as schizophrenia) have had many serious shortcomings -including lack of efficacy for some of the most troubling symptoms (e.g., cognitive impairment) and excessive tolerability and safety issues (including movement disorders and detrimental cardiometabolic effects). We seem to be entering a new era of psychopharmacology as exciting new therapeutic targets are identified and novel pharmacological strategies are developed and become part of our treatment armamentarium. In this March half-day Saturday Morning Live half-day program, we will focus on two targets showing tremendous promise for revolutionizing the treatment of serious mental illness -glutamate and cholinergic muscarinic receptors.



Saturday, March 22, 2025

7:00 am - 8:00 am

A Whole Glu World: Modulating Glutamatergic Neurotransmission in the Treatment of Mental Illness

Andrew J. Cutler, MD

The role of dysregulated glutamatergic neurotransmission in mental illnesses, including depression, is increasingly being recognized. In this presentation, Dr. Andrew Cutler will take a deep dive into the structure and function of N-methyl-D-aspartate receptors (NMDAR) and discuss the efficacy, safety, and tolerability of novel and emerging therapeutics that target NMDAR in the treatment of depression.

8:00 am - 9:00 am

Industry Session: Navigating the Patient Journey in Schizophrenia: Disease Management and an Option for Treatment

Charles Nguyen, MD, DFAPA

Sponsored by Intra-Cellular Therapies, Inc.

9:00 am – 9:05 am

Break

9:05 am – 9:35 am

Poster Session: Switching Patients With Schizophrenia From Intramuscular Paliperidone Palmitate Once-Monthly (PP1M) or Subcutaneous Once-Monthly Risperidone (RBP-7000) to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies

Andrew J. Cutler, MD

Sponsored by Teva Pharmaceuticals

9:35 am - 10:35 am

If You Musc: Modulation of Muscarinic Receptors in the Treatment of Schizophrenia

Hara Oyedeji, APRN, PMHNP, MSN, MSEd

In this talk, NP Hara Oyedeji will explore the role of muscarinic receptors in schizophrenia, highlighting their impact on positive, negative, and cognitive symptoms. The talk will cover novel M1, M4, and dual M1/M4 agonists and modulators, emphasizing their efficacy, safety, and potential to minimize side effects. Attendees will gain insights into emerging muscarinic-based treatments and how to integrate them into clinical practice as they become available.

10:35 am - 11:00 am



The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.



Program Faculty

Andrew J. Cutler, MD


Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Malvern, PA


Andrew J. Cutler, MD, attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology. He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD. Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He has been Board Certified in both Internal Medicine and Psychiatry.

Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.

Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.

Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.

read more +

Hara Oyedeji, APRN, PMHNP, MSN, MSEd


Founder and Lead Clinician of Fortitude Wellness Group, a Nurse Practitioner led Group Practice
Co-founder, Chief Operating Officer, and Medical Director at Greater Chesapeake Health and Wellness, LLC


Hara is a board-certified Psychiatric Nurse Practitioner currently working in outpatient care but has experience in inpatient and psychiatric hospital settings. She is the founder and lead clinician of her private practice, Fortitude Wellness Group and is the Chief Operating Ofcer and Medical Director of a CARF accredited Outpatient Mental Health Clinic, Greater Chesapeake Health and Wellness in Baltimore City. Hara completed her undergraduate degree at Rutgers University and her Master’s degree in education from Monmouth University in New Jersey. She completed her Master’s degree in nursing from the University of Maryland with her post-master's training as a psychiatric mental health nurse practitioner from Drexel University.

Her areas of expertise include severe mental illness and psychotic disorders for high-risk populations and she treats across the lifespan from children to adults. She also provides medication-assisted treatment for patients with co-occurring mental health and substance use disorders. As a national speaker and Key Opinion Leader (KOL) she has presented on disease states and pharmacology for mental health. This includes clinical perspectives of and approved treatment options for schizophrenia, bipolar disorder, depression and drug-induced movement disorders. She has presented at various conferences, including Nurse Practitioner Institute (NPI), the American Association of Nurse Practitioners (AANP), American Psychiatric Nurses Association (APNA), and Nurse Practitioners Association of Maryland (NPAM) of which she is also an active member.

Hara is a sitting Board Member for the non-prot organization Abilities Network which is committed to individualized community support for children, families and those with developmental disabilities. As an advocate for self-care and mental health issues affecting marginalized communities, Hara is committed to health equity and inspired by personal family members thriving in their journeys.

read more +